Anaphylaxis
Risk of severe allergic reaction. Seek urgent medical help if serious symptoms occur.
Leaflet SKYRIZI 55mg 55mg / 037ml solution for injection in pre-filled syringe
- Product code:
- W72064001
- Quantity:
- 1
- Indicated for:
- autoimmune inflammatory diseases
- Route of administration:
- injectable
- Substance:
- risankizumab (monoclonal antibody)
- ATC
- L04AC18 — Antineoplastic and immunomodulating agents | Immunosuppressants | Immunosuppressants | Interleukin inhibitors
Precautions:
Additional monitoring
This medicine is subject to additional monitoring.
Breastfeeding warning
Use during breastfeeding only on medical advice.
Pregnancy warning
Use during pregnancy only on medical advice.
Risankizumab is a monoclonal antibody used for the treatment of moderate to severe plaque psoriasis in adults. It works by inhibiting interleukin-23 (IL-23), a protein involved in inflammation, thereby reducing psoriasis symptoms.
The medication is administered as a subcutaneous injection, as directed by a doctor, usually once every few weeks. It is important for patients to follow the treatment regimen and inform the doctor of any unusual symptoms.
Patients should be aware of potential side effects, such as injection site reactions, respiratory infections, or headaches. It is important to inform the doctor of any unusual symptoms.
Common side effects include injection site reactions, respiratory infections, and headaches. In rare cases, severe reactions such as allergic reactions or serious infections may occur. Patients should be informed of these risks before administration.
The medication is administered as a subcutaneous injection, as directed by a doctor, usually once every few weeks. It is important for patients to follow the treatment regimen and inform the doctor of any unusual symptoms.
Patients should be aware of potential side effects, such as injection site reactions, respiratory infections, or headaches. It is important to inform the doctor of any unusual symptoms.
Common side effects include injection site reactions, respiratory infections, and headaches. In rare cases, severe reactions such as allergic reactions or serious infections may occur. Patients should be informed of these risks before administration.
General data about SKYRIZI 55mg 55mg / 037ml
- Substance:
- risankizumab
- Date of latest medicines list:
- 01-08-2026
- Product code:
- W72064001
- Concentration:
- 55mg / 037ml
- Pharmaceutical form:
- solution for injection in pre-filled syringe
- Quantity:
- 1
- Product type:
- Original
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Pharmaceutical forms available for risankizumab
Concentrations available for risankizumab
- 150mg/1ml
- 150mg/ml
- 55mg/037ml
- 60mg/ml
- 75mg/0.5ml
- 75mg/0.83ml